Lisata Therapeutics Inc. (LSTA)
| Bid | 2.32 |
| Market Cap | 20.42M |
| Revenue (ttm) | 1M |
| Net Income (ttm) | -19.98M |
| EPS (ttm) | -2.4 |
| PE Ratio (ttm) | -0.99 |
| Forward PE | -2.4 |
| Analyst | Buy |
| Ask | 2.55 |
| Volume | 2,801 |
| Avg. Volume (20D) | 13,365 |
| Open | 2.46 |
| Previous Close | 2.30 |
| Day's Range | 2.30 - 2.46 |
| 52-Week Range | 1.87 - 4.20 |
| Beta | 0.95 |
About LSTA
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for LSTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
4 hours ago · proactiveinvestors.com
Lisata eyes key trial milestones in 2025 as certepetide development gains momentumLisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its lead asset, certepetide, a novel peptide-based therapy being tested in a ...
2 weeks ago · proactiveinvestors.com
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMILisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors tha...
2 months ago · proactiveinvestors.com
Lisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMILisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss the company's strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Maz...
2 months ago · proactiveinvestors.com
Lisata Therapeutics partners with GATC Health to advance AI-driven drug developmentLisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading drug discovery firm leveraging artificial intelligence. The...
2 months ago · seekingalpha.com
Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call TranscriptLisata Therapeutics, Inc. (NASDAQ:LSTA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants John Menditto - Vice President of Investor Relations and Corporate Communica...
2 months ago · proactiveinvestors.com
Lisata Therapeutics CEO: 2025 to be ‘data-rich' as certepetide trials progressLisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a statement accompanying its full-year 2024 financial results. The pharmaceutical ...